Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses

Antiviral Research

Volumn 129, Issue , 2016, Pages 21-38

  McKimm Breschkin, Jennifer L ^a   Fry, Alicia M ^b  

^a CSIRO   (Australia)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antiviral; Influenza; Isirv AVG; Respiratory virus

Indexed keywords

ANTIVIRUS AGENT; DIPEPTIDYL PEPTIDASE IV; ERITORAN; FAVIPIRAVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LANINAMIVIR; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NITAZOXANIDE; OSELTAMIVIR; PERAMIVIR; PROTEIN M2; RNA DIRECTED RNA POLYMERASE; SIRTUIN; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG; VERDINEXOR; VIRUS NUCLEOPROTEIN; VIRUS SIALIDASE; VIS 410 ANTIBODY; ZANAMIVIR; AMANTADINE; ENZYME INHIBITOR; RIMANTADINE; SIALIDASE;

ANTIBODY DEPENDENT ENHANCEMENT; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HOST CELL; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFLUENZA; INFLUENZA A; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; OUTPATIENT; PRIORITY JOURNAL; PUBLIC HEALTH; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RHINOVIRUS INFECTION; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL RESPIRATORY TRACT INFECTION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS LOAD; VIRUS REPLICATION; VIRUS UNCOATING; CORONAVIRUS INFECTIONS; DRUG EFFECTS; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; PICORNAVIRIDAE INFECTIONS; RESPIRATORY TRACT INFECTIONS; TEXAS; VIROLOGY;

AMANTADINE; ANTIBODY-DEPENDENT ENHANCEMENT; ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; ORTHOMYXOVIRIDAE; OSELTAMIVIR; PICORNAVIRIDAE INFECTIONS; RESPIRATORY TRACT INFECTIONS; RIMANTADINE; SEVERE ACUTE RESPIRATORY SYNDROME; TEXAS; VIRUS REPLICATION;

EID: 84958970247     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.01.012     Document Type: Review

References (102)

1. AAPCID Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection Pediatrics 134 2014 e620 e638 10.1542/peds.2014-1666
2. P.J. Adabala, E.B. LeGresley, N. Bance, M. Niikura, and B.M. Pinto Exploitation of the catalytic site and 150 cavity for design of influenza A neuraminidase inhibitors J. Org. Chem. 78 2013 10867 10877 10.1021/jo401854w
3. M.J. Abzug, M.G. Michaels, E. Wald, R.F. Jacobs, J.R. Romero, P.J. Sanchez, G. Wilson, P. Krogstad, G.A. Storch, R. Lawrence, M. Shelton, A. Palmer, J. Robinson, P. Dennehy, S.K. Sood, G. Cloud, P. Jester, E.P. Acosta, R. Whitley, and D. Kimberlin A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis J. Pediatric Infect. Dis. Soc. 2015 10.1093/jpids/piv015
4. R.E. Amaro, R.V. Swift, L. Votapka, W.W. Li, R.C. Walker, and R.M. Bush Mechanism of 150-cavity formation in influenza neuraminidase Nat. Comm. 2 2011 388 10.1038/ncomms1390
5. C.R. Ballengee, and R.B. Turner Supportive treatment for children with the common cold Curr. Opin. Pediatr. 26 2014 114 118 10.1097/MOP.0000000000000047
6. I. Banerjee, Y. Miyake, S.P. Nobs, C. Schneider, P. Horvath, M. Kopf, P. Matthias, A. Helenius, and Y. Yamauchi Influenza A virus uses the aggresome processing machinery for host cell entry Science 346 2014 473 477 10.1126/science.1257037
7. S. Barrett, P.G. Mohr, P.M. Schmidt, and J.L. McKimm-Breschkin Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses PloS One 6 2011 e23627 10.1371/journal.pone.0023627
8. J.D. Bauman, D. Patel, S.F. Baker, R.S. Vijayan, A. Xiang, A.K. Parhi, L. Martinez-Sobrido, E.J. LaVoie, K. Das, and E. Arnold Crystallographic fragment screening and structure-based optimization yields a new class of influenza endonuclease inhibitors ACS Chem. Biol. 8 2013 2501 2508 10.1021/cb400400j
9. K.M. Bedard, M.L. Wang, S.C. Proll, Y.M. Loo, M.G. Katze, M. Gale Jr., and S.P. Iadonato Isoflavone agonists of IRF-3 dependent signaling have antiviral activity against RNA viruses J. Virol. 86 2012 7334 7344 10.1128/JVI.06867-11
10. G. Belardo, O. Cenciarelli, S. La Frazia, J.F. Rossignol, and M.G. Santoro Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro Antimicrob. Agents Chemother. 59 2015 1061 1069 10.1128/AAC.03947-14
11. J.A. Belser, X. Lu, K.J. Szretter, X. Jin, L.M. Aschenbrenner, A. Lee, S. Hawley, H. Kim do, M.P. Malakhov, M. Yu, F. Fang, and J.M. Katz DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection J. Infect. Dis. 196 2007 1493 1499 10.1086/522609
12. A.J. Burnham, T. Baranovich, and E.A. Govorkova Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance Antivir. Res. 100 2013 520 534 10.1016/j.antiviral.2013.08.023
13. R.A. Byrn, S.M. Jones, H.B. Bennett, C. Bral, M.P. Clark, M.D. Jacobs, A.D. Kwong, M.W. Ledeboer, J.R. Leeman, C.F. McNeil, M.A. Murcko, A. Nezami, E. Perola, R. Rijnbrand, K. Saxena, A.W. Tsai, Y. Zhou, and P.S. Charifson Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit Antimicrob. Agents Chemother. 59 2015 1569 1582 10.1128/AAC.04623-14
14. CDC Preventing Seasonal Flu with Vaccination 2015 http://www.cdc.gov/flu/protect/vaccine/index.htm (Accessed 28th July 2015)
15. CDC Seasonal Influenza (Flu):Treatment - Antiviral Drugs 2015 http://www.cdc.gov/flu/antivirals/index.htm (Accessed 28th July 2015)
16. S. Chalkias, M.R. Mackenzie, C. Gay, C. Dooley, F.M. Marty, R.B. Moss, T. Li, R.L. Routh, S.R. Walsh, and C.S. Tan DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation Transpl. Infect. Dis. 16 2014 141 144 10.1111/tid.12177
17. S. Challa, A.D. Scott, O. Yuzhakov, Y. Zhou, C.L. Tiong-Yip, N. Gao, J. Thresher, and Q. Yu Mechanism of action for respiratory syncytial virus inhibitor RSV604 Antimicrob. Agents Chemother. 59 2015 1080 1087 10.1128/AAC.04119-14
18. M.P. Clark, M.W. Ledeboer, I. Davies, R.A. Byrn, S.M. Jones, E. Perola, A. Tsai, M. Jacobs, K. Nti-Addae, U.K. Bandarage, M.J. Boyd, R.S. Bethiel, J.J. Court, H. Deng, J.P. Duffy, W.A. Dorsch, L.J. Farmer, H. Gao, W. Gu, K. Jackson, D.H. Jacobs, J.M. Kennedy, B. Ledford, J. Liang, F. Maltais, M. Murcko, T. Wang, M.W. Wannamaker, H.B. Bennett, J.R. Leeman, C. McNeil, W.P. Taylor, C. Memmott, M. Jiang, R. Rijnbrand, C. Bral, U. Germann, A. Nezami, Y. Zhang, F.G. Salituro, Y.L. Bennani, and P.S. Charifson Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2 J. Med. Chem. 57 2014 6668 6678 10.1021/jm5007275
19. ClinicalTrialsgov A Phase 2 Study of Vapendavir in Asthmatic Adults with Symptomatic Human Rhinovirus Infection (SPIRITUS) 2015 (Accessed 28th July 2015) https://www.clinicaltrials.gov/ct2/show/NCT02367313?term=vapendavir&rank=2
20. J. Deval, J. Hong, G. Wang, J. Taylor, L.K. Smith, A. Fung, S.K. Stevens, H. Liu, Z. Jin, N. Dyatkina, M. Prhavc, A.D. Stoycheva, V. Serebryany, J. Liu, D.B. Smith, Y. Tam, Q. Zhang, M.L. Moore, R. Fearns, S.M. Chanda, L.M. Blatt, J.A. Symons, and L. Beigelman Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2′-fluoro-4′-chloromethyl-cytidine triphosphate PLoS Pathog. 11 2015 e1004995 10.1371/journal.ppat.1004995
21. J. DeVincenzo, R. Lambkin-Williams, T. Wilkinson, J. Cehelsky, S. Nochur, E. Walsh, R. Meyers, J. Gollob, and A. Vaishnaw A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus Proc. Natl. Acad. Sci. U. S. A. 107 2010 8800 8805 10.1073/pnas.0912186107
22. J.P. DeVincenzo, M.W. McClure, J.A. Symons, H. Fathi, C. Westland, S. Chanda, R. Lambkin-Williams, P. Smith, Q. Zhang, L. Beigelman, L.M. Blatt, and J. Fry Activity of oral ALS-008176 in a respiratory syncytial virus challenge study N. Engl. J. Med. 373 2015 2048 2058 10.1056/NEJMoa1413275
23. J.P. DeVincenzo, R.J. Whitley, R.L. Mackman, C. Scaglioni-Weinlich, L. Harrison, E. Farrell, S. McBride, R. Lambkin-Williams, R. Jordan, Y. Xin, S. Ramanathan, T. O'Riordan, S.A. Lewis, X. Li, S.L. Toback, S.L. Lin, and J.W. Chien Oral GS-5806 activity in a respiratory syncytial virus challenge study N. Engl. J. Med. 371 2014 711 722 10.1056/NEJMoa1401184
24. L. Dirr, I.M. El-Deeb, P. Guillon, C.J. Carroux, L.M. Chavas, and M. von Itzstein The catalytic mechanism of human parainfluenza virus type 3 haemagglutinin-neuraminidase revealed Angew. Chem. Int. Ed. Engl. 54 2015 2936 2940 10.1002/anie.201412243
25. J. Dobson, R.J. Whitley, S. Pocock, and A.S. Monto Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials Lancet 385 2015 1729 1737 10.1016/S0140-6736(14)62449-1
26. J.L. Douglas, M.L. Panis, E. Ho, K.Y. Lin, S.H. Krawczyk, D.M. Grant, R. Cai, S. Swaminathan, X. Chen, and T. Cihlar Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms Antimicrob. Agents Chemother. 49 2005 2460 2466 10.1128/AAC.49.6.2460-2466.2005
27. K. Droebner, S. Pleschka, S. Ludwig, and O. Planz Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo Antivir. Res. 92 2011 195 203 10.1016/j.antiviral.2011.08.002
28. FDA Guidance for Industry Influenza: Developing Drugs for Treatment And/or Prophylaxis 2011 (Accessed Nov 10, 2015) http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM091219.pdf
29. B. Flannery, J. Clippard, R.K. Zimmerman, M.P. Nowalk, M.L. Jackson, L.A. Jackson, A.S. Monto, J.G. Petrie, H.Q. McLean, E.A. Belongia, M. Gaglani, L. Berman, A. Foust, W. Sessions, S.N. Thaker, S. Spencer, and A.M. Fry Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb. Mortal. Wkly. Rep. 64 2015 10 15
30. Y. Furuta, B.B. Gowen, K. Takahashi, K. Shiraki, D.F. Smee, and D.L. Barnard Favipiravir (T-705), a novel viral RNA polymerase inhibitor Antivir. Res. 100 2013 446 454 10.1016/j.antiviral.2013.09.015
31. P. Gerlach, H. Malet, S. Cusack, and J. Reguera Structural insights into bunyavirus replication and its regulation by the vRNA promoter Cell 161 2015 1267 1279 10.1016/j.cell.2015.05.006
32. E. Haasbach, C. Hartmayer, and O. Planz Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro Antivir. Res. 98 2013 319 324 10.1016/j.antiviral.2013.03.006
33. J. Haffizulla, A. Hartman, M. Hoppers, H. Resnick, S. Samudrala, C. Ginocchio, M. Bardin, and J.F. Rossignol Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial Lancet Infect. Dis. 14 2014 609 618 10.1016/S1473-3099(14)70717-0
34. F. Havers, S. Thaker, J.R. Clippard, M. Jackson, H.Q. McLean, M. Gaglani, A.S. Monto, R.K. Zimmerman, L. Jackson, J.G. Petrie, M.P. Nowalk, K.K. Moehling, B. Flannery, M.G. Thompson, and A.M. Fry Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season Clin. Infect. Dis. 59 2014 774 782 10.1093/cid/ciu422
35. F.G. Hayden Advances in antivirals for non-influenza respiratory virus infections Influenza Other Respir. Viruses 7 Suppl. 3 2013 36 43 10.1111/irv.12173
36. K.A. Hooper, J.E. Crowe Jr., and J.D. Bloom Influenza viruses with receptor-binding N1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice J. Virol. 89 2015 3737 3745 10.1128/JVI.00012-15
37. T. Jefferson, M.A. Jones, P. Doshi, C.B. Del Mar, R. Hama, M.J. Thompson, E.A. Spencer, I. Onakpoya, K.R. Mahtani, D. Nunan, J. Howick, and C.J. Heneghan Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children Cochrane Database Syst. Rev. 4 2014 CD008965 10.1002/14651858.CD008965.pub4
38. B.G. Jones, R.T. Hayden, and J.L. Hurwitz Inhibition of primary clinical isolates of human parainfluenza virus by DAS181 in cell culture and in a cotton rat model Antivir. Res. 100 2013 562 566 10.1016/j.antiviral.2013.09.014
39. P.S. Kerry, S. Mohan, R.J. Russell, N. Bance, M. Niikura, and B.M. Pinto Structural basis for a class of nanomolar influenza A neuraminidase inhibitors Sci. Rep. 3 2013 2871 10.1038/srep02871
40. S. Khurana, C.L. Loving, J. Manischewitz, L.R. King, P.C. Gauger, J. Henningson, and A.L. Vincent Golding, H., Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease Sci. Transl. Med. 5 2013 200ra114 10.1126/scitranslmed.3006366
41. J.H. Kim, R. Resende, T. Wennekes, H.M. Chen, N. Bance, S. Buchini, A.G. Watts, P. Pilling, V.A. Streltsov, M. Petric, R. Liggins, S. Barrett, J.L. McKimm-Breschkin, M. Niikura, and S.G. Withers Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity Science 340 2013 71 75 10.1126/science.1232552
42. E. Kowalinski, C. Zubieta, A. Wolkerstorfer, O.H. Szolar, R.W. Ruigrok, and S. Cusack Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 (2009) polymerase PLoS Pathog. 8 2012 e1002831 10.1371/journal.ppat.1002831
43. E. Koyuncu, H.G. Budayeva, Y.V. Miteva, D.P. Ricci, T.J. Silhavy, T. Shenk, and I.M. Cristea Sirtuins are evolutionarily conserved viral restriction factors mBio 5 2014 10.1128/mBio.02249-14
44. N. Lejal, B. Tarus, E. Bouguyon, S. Chenavas, N. Bertho, B. Delmas, R.W. Ruigrok, C. Di Primo, and A. Slama-Schwok Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus Antimicrob. Agents Chemother. 57 2013 2231 2242 10.1128/AAC.02335-12
45. S. Ludwig, R. Zell, M. Schwemmle, and S. Herold Influenza, a One Health paradigm-novel therapeutic strategies to fight a zoonotic pathogen with pandemic potential Int. J. Med. Microbiol. 304 2014 894 901 10.1016/j.ijmm.2014.08.016
46. R.L. Mackman, M. Sangi, D. Sperandio, J.P. Parrish, E. Eisenberg, M. Perron, H. Hui, L. Zhang, D. Siegel, H. Yang, O. Saunders, C. Boojamra, G. Lee, D. Samuel, K. Babaoglu, A. Carey, B.E. Gilbert, P.A. Piedra, R. Strickley, Q. Iwata, J. Hayes, K. Stray, A. Kinkade, D. Theodore, R. Jordan, M. Desai, and T. Cihlar Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study J. Med. Chem. 58 2015 1630 1643 10.1021/jm5017768
47. H. Marjuki, V.P. Mishin, A.P. Chesnokov, J.A. De La Cruz, A.M. Fry, J. Villanueva, and L.V. Gubareva An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality J. Infect. Dis. 210 2014 435 440 10.1093/infdis/jiu105
48. D. Marsolais, B. Hahm, K.B. Walsh, K.H. Edelmann, D. McGavern, Y. Hatta, Y. Kawaoka, H. Rosen, and M.B. Oldstone A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection Proc. Natl. Acad. Sci. U. S. A. 106 2009 1560 1565 10.1073/pnas.0812689106
49. J. McKimm-Breschkin VP-14637 ViroPharma Curr. Opin. Investigational Drugs 1 2000 425 427
50. M.J. Memoli, L. Czajkowski, S. Reed, R. Athota, T. Bristol, K. Proudfoot, S. Fargis, M. Stein, R.L. Dunfee, P.A. Shaw, R.T. Davey, and J.K. Taubenberger Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study Clin. Infect. Dis. 60 2015 693 702 10.1093/cid/ciu924
51. C.M. Midgley, J.T. Watson, W.A. Nix, A.T. Curns, S.L. Rogers, B.A. Brown, C. Conover, S.R. Dominguez, D.R. Feikin, S. Gray, F. Hassan, S. Hoferka, M.A. Jackson, D. Johnson, E. Leshem, L. Miller, J.B. Nichols, A.C. Nyquist, E. Obringer, A. Patel, M. Patel, B. Rha, E. Schneider, J.E. Schuster, R. Selvarangan, J.F. Seward, G. Turabelidze, M.S. Oberste, M.A. Pallansch, and S.I. Gerber EV-D68 Working Group. Severe respiratory illness associated with a nationwide outbreak of enterovirus D68 in the USA (2014): a descriptive epidemiological investigation Lancet Respir. Med. 3 11 2014 879 887
52. S. Mohan, P.S. Kerry, N. Bance, M. Niikura, and B.M. Pinto Serendipitous discovery of a potent influenza virus a neuraminidase inhibitor Angew. Chem. 53 2014 1076 1080 10.1002/anie.201308142
53. S. Mohan, S. McAtamney, T. Haselhorst, M. von Itzstein, and B.M. Pinto Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles J. Med. Chem. 53 2010 7377 7391 10.1021/jm100822f
54. P.G. Mohr, Y.M. Deng, and J.L. McKimm-Breschkin The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding Virol. J. 12 2015 67 10.1186/s12985-015-0295-3
55. R.B. Moss, C. Hansen, R.L. Sanders, S. Hawley, T. Li, and R.T. Steigbigel A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection J. Infect. Dis. 206 2012 1844 1851 10.1093/infdis/jis622
56. S.G. Muthuri, S. Venkatesan, P.R. Myles, J. Leonardi-Bee, T.S. Al Khuwaitir, A. Al Mamun, A.P. Anovadiya, E. Azziz-Baumgartner, C. Baez, M. Bassetti, B. Beovic, B. Bertisch, I. Bonmarin, R. Booy, V.H. Borja-Aburto, H. Burgmann, B. Cao, J. Carratala, J.T. Denholm, S.R. Dominguez, P.A. Duarte, G. Dubnov-Raz, M. Echavarria, S. Fanella, Z. Gao, P. Gerardin, M. Giannella, S. Gubbels, J. Herberg, A.L. Iglesias, P.H. Hoger, X. Hu, Q.T. Islam, M.F. Jimenez, A. Kandeel, G. Keijzers, H. Khalili, M. Knight, K. Kudo, G. Kusznierz, I. Kuzman, A.M. Kwan, I.L. Amine, E. Langenegger, K.B. Lankarani, Y.S. Leo, R. Linko, P. Liu, F. Madanat, E. Mayo-Montero, A. McGeer, Z. Memish, G. Metan, A. Mickiene, D. Mikic, K.G. Mohn, A. Moradi, P. Nymadawa, M.E. Oliva, M. Ozkan, D. Parekh, M. Paul, F.P. Polack, B.A. Rath, A.H. Rodriguez, E.B. Sarrouf, A.C. Seale, B. Sertogullarindan, M.M. Siqueira, J. Skret-Magierlo, F. Stephan, E. Talarek, J.W. Tang, K.K. To, A. Torres, S.H. Torun, D. Tran, T.M. Uyeki, A. Van Zwol, W. Vaudry, T. Vidmar, R.T. Yokota, P. Zarogoulidis, and J.S. Nguyen-Van-Tam Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data Lancet. Respir. Med. 2 2014 395 404 10.1016/S2213-2600(14)70041-4
57. H. Nair, D.J. Nokes, B.D. Gessner, M. Dherani, S.A. Madhi, R.J. Singleton, K.L. O'Brien, A. Roca, P.F. Wright, N. Bruce, A. Chandran, E. Theodoratou, A. Sutanto, E.R. Sedyaningsih, M. Ngama, P.K. Munywoki, C. Kartasasmita, E.A. Simoes, I. Rudan, M.W. Weber, and H. Campbell Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis Lancet 375 2010 1545 1555 10.1016/s0140-6736(10)60206-1
58. M.Q. Nicol, Y. Ligertwood, M.N. Bacon, B.M. Dutia, and A.A. Nash A novel family of peptides with potent activity against influenza A viruses J. Gen. Virol. 93 2012 980 986 10.1099/vir.0.038679-0
59. S.L. Noton, K. Nagendra, E.F. Dunn, M.E. Mawhorter, Q. Yu, and R. Fearns Respiratory syncytial virus inhibitor AZ-27 differentially inhibits different polymerase activities at the promoter J. Virol. 89 2015 7786 7798 10.1128/JVI.00530-15
60. L. Oestereich, A. Ludtke, S. Wurr, T. Rieger, C. Munoz-Fontela, and S. Gunther Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model Antivir. Res. 105 2014 17 21 10.1016/j.antiviral.2014.02.014
61. A.C. Palmenberg, and J.E. Gern Classification and evolution of human rhinoviruses Methods Mol. Biol. 1221 2015 1 10 10.1007/978-1-4939-1571-2-1
62. S. Pautus, P. Sehr, J. Lewis, A. Fortune, A. Wolkerstorfer, O. Szolar, D. Guilligay, T. Lunardi, J.L. Decout, and S. Cusack New 7-methylguanine derivatives targeting the influenza polymerase PB2 cap-binding domain J. Med. Chem. 56 2013 8915 8930 10.1021/jm401369y
63. J.M. Perreira, A.M. Aker, G. Savidis, C.R. Chin, W.M. McDougall, J.M. Portmann, P. Meraner, M.C. Smith, M. Rahman, R.E. Baker, A. Gauthier, M. Franti, and A.L. Brass RNASEK is a v-ATPase-associated factor required for endocytosis and the replication of rhinovirus, influenza a virus, and dengue virus Cell Rep. 12 2015 850 863 10.1016/j.celrep.2015.06.076
64. O. Perwitasari, S. Johnson, X. Yan, E. Howerth, S. Shacham, Y. Landesman, E. Baloglu, D. McCauley, S. Tamir, S.M. Tompkins, and R.A. Tripp Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo J. Virol. 88 2014 10228 10243 10.1128/JVI.01774-14
65. A. Pflug, D. Guilligay, S. Reich, and S. Cusack Structure of influenza A polymerase bound to the viral RNA promoter Nature 516 2014 355 360 10.1038/nature14008
66. O. Ramilo, R. Lagos, X. Saez-Llorens, J. Suzich, C.K. Wang, K.M. Jensen, B.S. Harris, G.A. Losonsky, and M.P. Griffin Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness Pediatr. Infec.t Dis. J. 33 2014 703 709 10.1097/INF.0000000000000240
67. S. Reich, D. Guilligay, A. Pflug, H. Malet, I. Berger, T. Crepin, D. Hart, T. Lunardi, M. Nanao, R.W. Ruigrok, and S. Cusack Structural insight into cap-snatching and RNA synthesis by influenza polymerase Nature 516 2014 361 366 10.1038/nature14009
68. J.F. Rossignol Nitazoxanide: a first-in-class broad-spectrum antiviral agent Antivir. Res. 110 2014 94 103 10.1016/j.antiviral.2014.07.014
69. M. Sato, M. Ito, S. Suzuki, H. Sakuma, A. Takeyama, S. Oda, M. Watanabe, K. Hashimoto, K. Miyazaki, Y. Kawasaki, and M. Hosoya Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants Antimicrob. Agents Chemother. 59 2015 1643 1649 10.1128/AAC.04263-14
70. K.A. Shirey, W. Lai, A.J. Scott, M. Lipsky, P. Mistry, L.M. Pletneva, C.L. Karp, J. McAlees, T.L. Gioannini, J. Weiss, W.H. Chen, R.K. Ernst, D.P. Rossignol, F. Gusovsky, J.C. Blanco, and S.N. Vogel The TLR4 antagonist eritoran protects mice from lethal influenza infection Nature 497 2013 498 502 10.1038/nature12118
71. F.P. Silveira, R. Abdel-Massih, T. Bogdanovich, D.L. Pakstis, R.L. Routh, and R.B. Moss Treatment of resistant influenza virus infection in a hospitalized patient with cystic fibrosis with DAS181, a host-directed antiviral Antivir. Ther. 2015 10.3851/IMP2977
72. E.A. Simoes, J.P. DeVincenzo, M. Boeckh, L. Bont, J.E. Crowe Jr., P. Griffiths, F.G. Hayden, R.L. Hodinka, R.L. Smyth, K. Spencer, S. Thirstrup, E.E. Walsh, and R.J. Whitley Challenges and opportunities in developing respiratory syncytial virus therapeutics J. Infect. Dis. 211 Suppl. 1 2015 S1 S20 10.1093/infdis/jiu828
73. D.M. Skowronski, G. De Serres, N.S. Crowcroft, N.Z. Janjua, N. Boulianne, T.S. Hottes, L.C. Rosella, J.A. Dickinson, R. Gilca, P. Sethi, N. Ouhoummane, D.J. Willison, I. Rouleau, M. Petric, K. Fonseca, S.J. Drews, A. Rebbapragada, H. Charest, M.E. Hamelin, G. Boivin, J.L. Gardy, Y. Li, T.L. Kwindt, D.M. Patrick, and R.C. Brunham Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada PLoS Med. 7 2010 e1000258 10.1371/journal.pmed.1000258
74. E.C. Smith, H. Blanc, M.C. Surdel, M. Vignuzzi, and M.R. Denison Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics PLoS Pathog. 9 2013 e1003565 10.1371/journal.ppat.1003565
75. S. Stauffer, Y. Feng, F. Nebioglu, R. Heilig, P. Picotti, and A. Helenius Stepwise priming by acidic pH and a high K+ concentration is required for efficient uncoating of influenza A virus cores after penetration J. Virol. 88 2014 13029 13046 10.1128/JVI.01430-14
76. A. Stevaert, R. Dallocchio, A. Dessi, N. Pala, D. Rogolino, M. Sechi, and L. Naesens Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease J. Virol. 87 2013 10524 10538 10.1128/JVI.00832-13
77. A. Stevaert, S. Nurra, N. Pala, M. Carcelli, D. Rogolino, C. Shepard, R.A. Domaoal, B. Kim, M. Alfonso-Prieto, S.A. Marras, M. Sechi, and L. Naesens An integrated biological approach to guide the development of metal-chelating inhibitors of influenza virus PA endonuclease Mol. Pharmacol. 87 2015 323 337 10.1124/mol.114.095588
78. V.A. Streltsov, P. Pilling, S. Barrett, and J.L. McKimm-Breschkin Catalytic mechanism and novel receptor binding sites of human parainfluenza virus type 3 hemagglutinin-neuraminidase (hPIV3 HN) Antivir. Res. 123 2015 216 223 10.1016/j.antiviral.2015.08.014
79. J. Sui, D.R. Aird, A. Tamin, A. Murakami, M. Yan, A. Yammanuru, H. Jing, B. Kan, X. Liu, Q. Zhu, Q.A. Yuan, G.P. Adams, W.J. Bellini, J. Xu, L.J. Anderson, and W.A. Marasco Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway PLoS Pathog. 4 2008 e1000197 10.1371/journal.ppat.1000197
80. J. Sui, M. Deming, B. Rockx, R.C. Liddington, Q.K. Zhu, R.S. Baric, and W.A. Marasco Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness J. Virol. 88 2014 13769 13780 10.1128/JVI.02232-14
81. J. Sui, W.C. Hwang, S. Perez, G. Wei, D. Aird, L.M. Chen, E. Santelli, B. Stec, G. Cadwell, M. Ali, H. Wan, A. Murakami, A. Yammanuru, T. Han, N.J. Cox, L.A. Bankston, R.O. Donis, R.C. Liddington, and W.A. Marasco Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses Nat. Struct. Mol. Biol. 16 2009 265 273 10.1038/nsmb.1566
82. E. Takashita, M. Kiso, S. Fujisaki, M. Yokoyama, K. Nakamura, M. Shirakura, H. Sato, T. Odagiri, Y. Kawaoka, and M. Tashiro Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan Antimicrob. Agents Chemother. 59 2015 2607 2617 10.1128/AAC.04836-14
83. W.W. Tang, R. Grewal, and S. Shresta Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models Curr. Opin. Virol. 13 2015 61 66 10.1016/j.coviro.2015.04.007
84. X.C. Tang, S.S. Agnihothram, Y. Jiao, J. Stanhope, R.L. Graham, E.C. Peterson, Y. Avnir, A.S. Tallarico, J. Sheehan, Q. Zhu, R.S. Baric, and W.A. Marasco Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution Proc. Natl. Acad. Sci. U. S. A. 111 2014 E2018 E2026 10.1073/pnas.1402074111
85. E.B. Tarbet, A.H. Vollmer, B.L. Hurst, D.L. Barnard, Y. Furuta, and D.F. Smee In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus Arch. Virol. 159 2014 1279 1291 10.1007/s00705-013-1922-1
86. B. Tarus, H. Bertrand, G. Zedda, C. Di Primo, S. Quideau, and A. Slama-Schwok Structure-based design of novel naproxen derivatives targeting monomeric nucleoprotein of influenza A virus J. Biomol. Struct. Dyn. 33 2015 1899 1912 10.1080/07391102.2014.979230
87. O. Terrier, A. Diederichs, J. Dubois, G. Cartet, B. Lina, J.C. Bourdon, and M. Rosa-Calatrava Influenza NS1 interacts with p53 and alters its binding to p53-responsive genes, in a promoter-dependent manner FEBS Lett. 587 2013 2965 2971 10.1016/j.febslet.2013.08.006
88. K. Tharakaraman, V. Subramanian, K. Viswanathan, S. Sloan, H.L. Yen, D.L. Barnard, Y.H. Leung, K.J. Szretter, T.J. Koch, J.C. Delaney, G.J. Babcock, G.N. Wogan, R. Sasisekharan, and Z. Shriver A broadly neutralizing human monoclonal antibody is effective against H7N9 Proc. Natl. Acad. Sci. U. S. A. 2015 10.1073/pnas.1502374112
89. C.L. Tiong-Yip, L. Aschenbrenner, K.D. Johnson, R.E. McLaughlin, J. Fan, S. Challa, H. Xiong, and Q. Yu Characterization of a respiratory syncytial virus L protein inhibitor Antimicrob. Agents Chemother. 58 2014 3867 3873 10.1128/AAC.02540-14
90. N. van Doremalen, and V.J. Munster Animal models of Middle East respiratory syndrome coronavirus infection Antivir. Res. 2015 10.1016/j.antiviral.2015.07.005
91. A. Waghmare, T. Wagner, R. Andrews, S. Smith, J. Kuypers, M. Boeckh, R. Moss, and J.A. Englund Successful treatment of parainfluenza virus respiratory tract infection with DAS181 in 4 immunocompromised children J. Pediatr. Infect. Dis. Soc. 4 2015 114 118 10.1093/jpids/piu039
92. K.B. Walsh, J.R. Teijaro, P.R. Wilker, A. Jatzek, D.M. Fremgen, S.C. Das, T. Watanabe, M. Hatta, K. Shinya, M. Suresh, Y. Kawaoka, H. Rosen, and M.B. Oldstone Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus Proc. Natl. Acad. Sci. U. S. A. 108 2011 12018 12023 10.1073/pnas.1107024108
93. J. Wang, F. Li, and C. Ma Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses Biopolymers 104 2015 291 309 10.1002/bip.22623
94. J. Wang, Y. Wu, C. Ma, G. Fiorin, L.H. Pinto, R.A. Lamb, M.L. Klein, and W.F. Degrado Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus Proc. Natl. Acad. Sci. U. S. A. 110 2013 1315 1320 10.1073/pnas.1216526110
95. M. Wang, J. Qi, Y. Liu, C.J. Vavricka, Y. Wu, Q. Li, and G.F. Gao Influenza A virus N5 neuraminidase has an extended 150-cavity J. Virol. 85 2011 8431 8435 10.1128/JVI.00638-11
96. K.M. White, P. De Jesus, Z. Chen, P. Abreu Jr., E. Barile, P.A. Mak, P. Anderson, Q.T. Nguyen, A. Inoue, S. Stertz, R. Koenig, M. Pellecchia, P. Palese, K. Kuhen, A. Garcia-Sastre, S.K. Chanda, and M.L. Shaw A potent anti-influenza compound blocks fusion through stabilization of the prefusion conformation of the hemagglutinin protein ACS Infect. Dis. 1 2015 98 109 10.1021/id500022h
97. R.J. Whitley, C.A. Boucher, B. Lina, J.S. Nguyen-Van-Tam, A. Osterhaus, M. Schutten, and A.S. Monto Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the influenza resistance information study (IRIS) Clin. Infect. Dis. 56 2013 1197 1205 10.1093/cid/cis1220
98. WHO Meetings of the WHO working group on surveillance of influenza antiviral susceptibility-Geneva, November 2011 and June 2012 Wkly. Epidemiol. Rec. 87 39 2012 369 374
99. Y. Wu, M. Cho, D. Shore, M. Song, J. Choi, T. Jiang, Y.Q. Deng, M. Bourgeois, L. Almli, H. Yang, L.M. Chen, Y. Shi, J. Qi, A. Li, K.S. Yi, M. Chang, J.S. Bae, H. Lee, J. Shin, J. Stevens, S. Hong, C.F. Qin, G.F. Gao, S.J. Chang, and R.O. Donis A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus Nat. Comm. 6 2015 7708 10.1038/ncomms8708
100. R.M. Zellweger, R. Miller, W.E. Eddy, L.J. White, R.E. Johnston, and S. Shresta Role of humoral versus cellular responses induced by a protective dengue vaccine candidate PLoS Pathog. 9 2013 e1003723 10.1371/journal.ppat.1003723
101. J.M. Zenilman, E.J. Fuchs, C.W. Hendrix, C. Radebaugh, R. Jurao, S.U. Nayak, R.G. Hamilton, and J. McLeod Griffiss Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults Antivir. Res. 123 2015 114 119 10.1016/j.antiviral.2015.09.008
102. J. Zhuge, E. Vail, J.L. Bush, L. Singelakis, W. Huang, S.M. Nolan, J.P. Haas, H. Engel, M. Della Posta, E.C. Yoon, J.T. Fallon, and G. Wang Evaluation of a real-time reverse transcription-PCR assay for detection of enterovirus D68 in clinical samples from an outbreak in New York state in 2014 J. Clin. Microbiol. 53 2015 1915 1920 10.1128/JCM.00358-15